- Trials with a EudraCT protocol (496)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
496 result(s) found for: Progestogen-only contraception.
Displaying page 1 of 25.
EudraCT Number: 2020-003688-25 | Sponsor Protocol Number: INS1007-301 | Start Date*: 2021-04-08 | |||||||||||
Sponsor Name:Insmed Incorporated | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibros... | |||||||||||||
Medical condition: Non-Cystic Fibrosis Bronchiectasis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PT (Completed) DK (Completed) NL (Completed) IE (Completed) HU (Completed) GR (Completed) PL (Completed) BG (Completed) LT (Prematurely Ended) SK (Completed) AT (Completed) FR (Completed) EE (Prematurely Ended) BE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-006044-14 | Sponsor Protocol Number: EB05-04-2020 | Start Date*: 2021-10-25 | ||||||||||||||||
Sponsor Name:Edesa Biotech Research Inc. | ||||||||||||||||||
Full Title: A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of EB05 + SOC vs. placebo + SOC in adult hospitalized patients with COVID19 | ||||||||||||||||||
Medical condition: SARS-CoV-2 Positive Pneumonia - level 3-7 in the nine-point COVID-19 severity scale: | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003474-27 | Sponsor Protocol Number: HepNet-aHCV-V | Start Date*: 2019-03-11 | |||||||||||
Sponsor Name:Hannover Medical School | |||||||||||||
Full Title: Multicenter trial for the treatment of acute Hepatitis C for 8 weeks with Sofosbuvir/Velpatasvir fix dose combination - The HepNet Acute HCV-V study | |||||||||||||
Medical condition: Adults with acute hepatitis C virus (HCV) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003921-27 | Sponsor Protocol Number: DORAGEN | Start Date*: 2019-06-25 |
Sponsor Name:Lluita contra la SIDA Foundation | ||
Full Title: Doravirine concentrations and antiviral activity in genital fluids in HIV-1 infected individuals. | ||
Medical condition: HIV infected individuals | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2019-003503-35 | Sponsor Protocol Number: PAINTX | Start Date*: 2020-02-03 |
Sponsor Name:Region Östergötland | ||
Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Effect of Botulinum Toxin A on Patients with Atypical Odontalgia/Persistent Dentoalveolar Pain. | ||
Medical condition: Atypical Odontalgia/Persistent Dentoalveolar Pain | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003351-65 | Sponsor Protocol Number: RDD110 | Start Date*: 2016-03-16 |
Sponsor Name:RDD Pharma Ltd. | ||
Full Title: The Effect of Intra-anal Nifedipine, Used As Add-on to Conservative Therapy, on Pain in Patients with Anal Fissure | ||
Medical condition: Anal Fissure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BG (Completed) PL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000121-32 | Sponsor Protocol Number: 68284528MMY2001 | Start Date*: 2019-09-03 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma | |||||||||||||
Medical condition: Relapsed or Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002044-26 | Sponsor Protocol Number: 104438 | Start Date*: 2005-07-28 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A randomized, double-blind, placebo-controlled, post-marketing phase III Study to evaluate the efficacy of GSK Biologicals’ influenza vaccine (Fluarix™) administered intramuscularly in adults | ||
Medical condition: Immunization against influenza in male and female subjects aged 18 to 64 years | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001242-35 | Sponsor Protocol Number: 68284528MMY3004 | Start Date*: 2021-08-02 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA... | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) NO (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) FI (Trial now transitioned) NL (Ongoing) CZ (Trial now transitioned) ES (Ongoing) HU (Ongoing) AT (Trial now transitioned) IE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001259-29 | Sponsor Protocol Number: UoL001306 | Start Date*: 2019-03-12 | |||||||||||
Sponsor Name:University of LIverpool | |||||||||||||
Full Title: A PHASE 1B/2A STUDY TO ASSESS THE TOLERABILITY AND ADVERSE EFFECT PROFILE OF CYSTEAMINE (CYSTAGON) IN ADULTS AND CHILDREN WITH HOMOZYGOUS ΔF508 CYSTIC FIBROSIS, IN PATIENTS TAKING EPIGALLOCATECHIN-... | |||||||||||||
Medical condition: DeltaF508 Homozygous Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001528-16 | Sponsor Protocol Number: INS1009-202 | Start Date*: 2022-05-30 | |||||||||||
Sponsor Name:Insmed Incorporated | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to valuate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in participants with Pu... | |||||||||||||
Medical condition: Participants with Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003050-32 | Sponsor Protocol Number: FAB122-CT-2201 | Start Date*: 2023-02-21 |
Sponsor Name:Ferrer Internacional S.A. | ||
Full Title: A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis | ||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Prematurely Ended) PL (Prematurely Ended) DE (Completed) SE (Completed) BE (Completed) ES (Completed) PT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000120-33 | Sponsor Protocol Number: BAY86-5321/16598 | Start Date*: 2015-08-26 | ||||||||||||||||
Sponsor Name:Bayer HealthCare AG | ||||||||||||||||||
Full Title: An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two differen... | ||||||||||||||||||
Medical condition: Neovascular Age-Related Macular Degeneration (nAMD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) CZ (Completed) SK (Completed) PT (Completed) LT (Completed) AT (Completed) GB (GB - no longer in EU/EEA) ES (Completed) DE (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003578-34 | Sponsor Protocol Number: 54135419TRD3008 | Start Date*: 2016-08-02 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression | |||||||||||||
Medical condition: Treatment-resistant Major Depression | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) ES (Ongoing) PL (Completed) HU (Completed) CZ (Completed) SK (Completed) LT (Completed) AT (Completed) FI (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013020-23 | Sponsor Protocol Number: RAA09-002 | Start Date*: 2010-03-23 | |||||||||||
Sponsor Name:King's College London | |||||||||||||
Full Title: A Pilot study of cognitive enhancer and cognitive training combination – Testing a therapeutic paradigm for cognitive impairment in schizophrenia | |||||||||||||
Medical condition: Cognitive impairment associated with schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000357-41 | Sponsor Protocol Number: APC040 | Start Date*: 2013-08-28 |
Sponsor Name:The Alimentary Pharmabiotic Centre, University College Cork | ||
Full Title: Identification of the Microbiota Dependent Response to Rifaximin in Irritable Bowel Syndrome Patients | ||
Medical condition: Irritable Bowel Syndrome | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-000799-33 | Sponsor Protocol Number: 001 | Start Date*: 2007-06-22 |
Sponsor Name:Universitätsklinikum Essen | ||
Full Title: A Study of the efficacy and safety of Rizatriptan 10 mg PRD in the treatment of acute migraine in patients with non satisfactory response to previous pharmacologic treatment | ||
Medical condition: acute migraine | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001046-19 | Sponsor Protocol Number: ORA-D-N01B | Start Date*: 2020-08-13 |
Sponsor Name:Oramed Ltd. | ||
Full Title: An Open-Label Multi-Center Study to Assess the Safety and Potential of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients with Nonalcoholic Steatohepatitis (NASH) | ||
Medical condition: Type 2 Diabetes Patients with Nonalcoholic Steatohepatitis (NASH) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005129-99 | Sponsor Protocol Number: TA799-013 | Start Date*: 2021-02-10 | |||||||||||
Sponsor Name:VectivBio AG | |||||||||||||
Full Title: A multicenter, open-label, metabolic balance study to evaluate the effects of apraglutide on intestinal absorption in adult subjects with short bowel syndrome, intestinal failure (SBS-IF), and colo... | |||||||||||||
Medical condition: short bowel syndrome, intestinal failure (SBS-IF), colon-in-continuity (CIC) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004204-39 | Sponsor Protocol Number: 108701 | Start Date*: 2007-02-01 | |||||||||||
Sponsor Name:GLAXO SMITHKLINE | |||||||||||||
Full Title: A randomized, open label, multicentre study to compare the pharmaco-economic implications of an analgesia based regimen with remifentanil and a conventional sedation based regimen using propofol in... | |||||||||||||
Medical condition: Medical and post surgical ICU patient requiring analgesia and sedation. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
